𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Requiring a CSF amyloid-β42 biomarker for a prodromal AD research diagnosis does not result in better clinical trials: Simulations from the ADNI database

✍ Scribed by Lon S. Schneider; Richard E. Kennedy; Gary R. Cutter


Book ID
118466097
Publisher
Elsevier Science
Year
2010
Tongue
English
Weight
43 KB
Volume
6
Category
Article
ISSN
1552-5260

No coin nor oath required. For personal study only.